Experimental CAR-T therapy aims to tame lupus, myositis, and ITP
NCT ID NCT07174843
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times
Summary
This early-phase study tests a new cell therapy called BZE2204 in 20 people with lupus, myositis, or immune thrombocytopenia (ITP) that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and reset the immune system. The main goals are to check safety and see if it can control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Mengchao Cancer Hospital
RECRUITINGShanghai, Shanghai Municipality, 200240, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BZE2204 CAR-T cells (a type of immune cell therapy targeting CD19, CD22, and BCMA proteins)
What this could lead to
If it works, this could offer a new way to control severe autoimmune diseases like lupus, myositis, and ITP by resetting the immune system.
What could go wrong
This is a very early, small trial with only 20 people. CAR-T therapy can cause serious side effects like cytokine release syndrome. It may not work for all patients or provide lasting benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.